Pfizer's analysis of the TALAPRO-2 trial is like "somebody shooting an arrow at the wall and then painting a target around it," the FDA's Richard Pazdur said. (Shutterstock)
Learn what's happening at the US FDA. On the go.
Derrick Gingery and the team bring you a weekly "Drug Fix".
